

REMARKS

Claims 1-3 were rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over U.S. Patent No. 6,545,182 and U.S. Patent No. 6,313,172. Submitted herewith are terminal disclaimers disclaiming these Patents. Thus, this is believed to overcome the rejections.

In light of the terminal disclaimers filed herein, Applicants respectfully request that Examiner pass the claims to issue.

Please charge Deposit Account 01-0885 for the extension fees and any other fees due in this case.

Respectfully submitted,

/Brent A. Johnson/

Brent A. Johnson

Registration No. 51,851

Agent of Record

Telephone: 714/246-4348

Telecopier: 714/246-4249

Date: September 13, 2006

Please address all correspondence and inquiries to:

Brent A. Johnson (T2-7H)

Allergan, Inc.

2525 Dupont Drive

Irvine, CA 92612

Tel: 714.246.4348

Fax: 714.246.4249